Engmab Sarl

Bristol-myers Squibb Compnay

Lamkap Bio Beta Ltd.

Engmab Ag

Lamkap Bio Alpha Ag

Engmab Beta Holdings LLC

Lamkap Bio Beta Ag

Klaus Strein

Minh Diem Vu

Christian Klein

Ekkehard Moessner

Pablo Umana

Anne Freimoser-Grundschober

Oliver Ast

Samuel Moser

Ralf Hosse

Marina Bacac

Tanja Fauti

Wolfgang Schaefer

Joerg Thomas Regula

Michael Molhoj

Stefan Klostermann

Lydia Jasmin Hanisch

Ramona Murr

Sabine Jung-Imhof

Tina Weinzierl

Lydia Jasmin Duerner

Vanessa Buatois

Jesus Fernado San Miguel Izquierdo

Bruno David Lourenco Paiva

Camille Delon

Stefano Majocchi

Sara Majocchi

Anne Freimoser-grundschober

Erich Hunziker

The present invention relates to bispecific antibodies which bind to human carcinoembryonic antigen CEACAM5 (CEA) and human CD3ε. In addition, the present invention relates to polynucleotides encoding such bispecific antibodies and vectors and host cells comprising such polynucleotides. The invention further relates to methods for selecting and producing such antibodies and to methods of using such antibodies in the treatment of diseases.

Bispecific antibodies against CEACAM5 and CD3

The present invention relates to bispecific antibodies against ROR1 and CD3, their manufacture and use.

Bispecific antibodies against CD3EPSILON and ROR1

The invention provides bispecific antibodies binding to human carcinoembryonic antigen CEACAM5 and human CD47, polynucleotides encoding such bispecific antibodies and vectors and host cells comprising such polynucleotides. The invention further provides methods for selecting and producing such antibodies and methods of using such antibodies in the treatment of diseases in monotherapy as well in combination.

Bispecific antibodies against CEACAM5 and CD47

The invention relates to a bispecific antibody specifically binding to human B cell maturation antigen (BCMA) and to human CD3&#x3f5; (CD3) together with an immunotherapeutic drug for combined use in treating multiple myeloma.

Bispecific antibody against BCMA and CD3 and an immunological drug for combined use in treating multiple myeloma

An antibody specifically binding to human BCMA, characterized in that the binding of said antibody is not reduced by APRIL and not reduced by BAFF, said antibody does not alter APRIL-dependent NF-&#x3ba;B activation, BAFF-dependent NF-&#x3ba;B activation, and does not alter NF-&#x3ba;B activation without BAFF and APRIL is useful as a therapeutic agent.

Method for the selection of antibodies against BCMA

The invention relates to new antibodies against BCMA, their manufacture and use.

Monoclonal antibodies against BCMA

A bispecific bi- or trivalent antibody specifically binding to the two targets which are extracellular domain of human B cell maturation antigen (BCMA) and human CD3&#x3b5;, wherein the variable domains VL and VH in a light chain and the respective heavy chain are replaced by each other, characterized in comprising a constant domain CL wherein the amino acid at position 124 is substituted independently by lysine (K), arginine (R) or histidine (H) (numbering according to Kabat), and in the respective constant domain CH1 the amino acid at position 147 and the amino acid at position 213 is substituted independently by glutamic acid (E), or aspartic acid (D) (numbering according to EU index of Kabat). Also the manufacture and use of said antibody.

Bispecific antibodies against CD3&#x3f5; and BCMA

A bispecific antibody specifically binding to the two targets human CD3&#x3b5; and human BCMA, wherein the variable domains of one antibody portion are replaced by each other, and characterized in that the binding of said antibody is not reduced by APRIL and not reduced by BAFF, said antibody does not alter APRIL-dependent NF-&#x3ba;B activation, BAFF-dependent NF-&#x3ba;B activation, and does not alter NF-&#x3ba;B activation without BAFF and APRIL is useful as a therapeutic agent.

Bispecific antibodies against CD3 and BCMA

Growing community of inventors

Weinheim, Germany

Klaus Strein